Anlon Healthcare

AHCLPharmaceuticals
124.38+0.00 (+0.00%)
As on 29 Jan 2026, 10:37 amMarket Closed

Fundamental Score

...

Anlon Healthcare Share Price Live NSE/BSE

No data
High
0.00
Low
0.00
Volume
0
Change
+0.00%

Profitability Metrics

Excellent

Return on Equity

40.45%
Excellent

Return on Capital Employed

24.83%
Excellent

Operating Profit Margin (5Y)

16.42%
Poor

Dividend Yield

0.00%

Valuation Metrics

Poor

Price to Earnings

32.28x

Market Capitalization

879.52 (Cr)

Industry P/E

31.77x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

259.85%
Excellent

YoY Quarterly Sales Growth

115.97%

Sales Growth (5Y)

N/A

EPS Growth (5Y)

N/A

Profit Growth (5Y)

N/A

Financial Health

Excellent

Debt to Equity

0.27x
Excellent

Interest Coverage

7.64x
Poor

Free Cash Flow (5Y)

-47.27 (Cr)

Ownership Structure

Good

Promoter Holding

52.68%
Poor

FII Holding

0.00%
Poor

DII Holding

2.83%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
52.68%
Promoter Holding
879.52 (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of AHCL across key market metrics for learning purposes.

Positive Indicators

9 factors identified

Strong Return on Equity (40.45%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (24.83%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Operating Margins (16.42%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Robust Profit Growth (259.85%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Strong Revenue Growth (115.97%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.

Conservative Debt Levels (D/E: 0.27)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (7.64x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Balanced Promoter Holding (52.68%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

4 factors identified

Negative Free Cash Flow (₹-47.27 Cr over 5Y)

Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.

Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.

Limited Institutional Interest (FII+DII: 2.83%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Financial Statements

Comprehensive financial data for Anlon Healthcare

About AHCL

Business Overview

Anlon Healthcare Limited manufactures and sells advance pharmaceutical intermediates in India and internationally. The company offers active pharmaceutical ingredients (API); nutraceutical API products; personal care ingredients; and veterinary API products. Its products are used in anti-inflammatory (NSAID), analgesic, antipyretic, antihistamine, antidepressant, antipsychotic, anticoagulant, antihypertensive, nutrition, anti-arrhythmic, anti-hyper parathyroid, antiplatelet, ant diabetic, gastroesophageal reflux disease (GERD), and anti-rheumatic therapeutics areas. The company was incorporated in 2013 and is based in Rajkot, India.

Company Details

Symbol:AHCL
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. Punitkumar Rameshbhai Rasadia
Chairman & MD
Mr. Hiteshkumar Bavanjibhai Makwana
Chief Financial Officer
Ms. Amitabhen Chhaganbhai Pragada
Company Secretary & Compliance Officer

AHCL Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)40.45%
Return on Capital Employed24.83%
Operating Profit Margin (5Y)16.42%
Debt to Equity Ratio0.27
Interest Coverage Ratio7.64

Growth & Valuation

Sales Growth (5Y)N/A%
Profit Growth (5Y)N/A%
EPS Growth (5Y)N/A%
YoY Quarterly Profit Growth259.85%
YoY Quarterly Sales Growth115.97%

Frequently Asked Questions

What is the current price of Anlon Healthcare (AHCL)?

As of 29 Jan 2026, 10:37 am IST, Anlon Healthcare (AHCL) is currently trading at ₹124.38. The stock has a market capitalization of ₹879.52 (Cr).

Is AHCL share price Overvalued or Undervalued?

AHCL is currently trading at a P/E ratio of 32.28x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Overvalued against its sector peers.

What factors affect the Anlon Healthcare share price?

Key factors influencing AHCL's price include its quarterly earnings growth (Sales Growth: 115.97%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).

Is Anlon Healthcare a good stock for long-term investment?

Anlon Healthcare shows a 5-year Profit Growth of N/A% and an ROE of 40.45%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.27 before investing.

How does Anlon Healthcare compare with its industry peers?

Anlon Healthcare competes with major peers in the Pharmaceuticals. Investors should compare AHCL's P/E of 32.28x and ROE of 40.45% against the industry averages to determine its competitive standing.

What is the P/E ratio of AHCL and what does it mean?

AHCL has a P/E ratio of 32.28x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹32 for every ₹1 of annual earnings.

How is AHCL performing according to Bull Run's analysis?

AHCL has a Bull Run fundamental score of 49/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.

What sector and industry does AHCL belong to?

AHCL operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Anlon Healthcare.

What is Return on Equity (ROE) and why is it important for AHCL?

AHCL has an ROE of 40.45%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Anlon Healthcare generates profits from shareholders' equity.

How is AHCL's debt-to-equity ratio and what does it indicate?

AHCL has a debt-to-equity ratio of 0.27, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.

What is AHCL's dividend yield and is it a good dividend stock?

AHCL offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.

How has AHCL grown over the past 5 years?

AHCL has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.

What is the promoter holding in AHCL and why does it matter?

Promoters hold 52.68% of AHCL shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.

What is AHCL's market capitalization category?

AHCL has a market capitalization of ₹880 crores, placing it in the Small-cap category.

How volatile is AHCL stock?

AHCL has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.

What is the 52-week high and low for AHCL?

AHCL has a 52-week high of ₹N/A and low of ₹N/A.

What is AHCL's operating profit margin trend?

AHCL has a 5-year average Operating Profit Margin (OPM) of 16.42%, indicating the company's operational efficiency.

How is AHCL's quarterly performance?

Recent quarterly performance shows YoY Sales Growth of 115.97% and YoY Profit Growth of 259.85%.

What is the institutional holding pattern in AHCL?

AHCL has FII holding of 0.00% and DII holding of 2.83%. Significant institutional holding often suggests professional confidence in the stock.